Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: A meta-analysis of randomized controlled trials
BMC Nephrology | Aug 30, 2017
Xie Y, et al. – This study targeted paricalcitol versus vitamin D receptor activators (VDRAs) regarding its comparative efficacy and safety for dialysis patients with secondary hyperparathyroidism (SHPT). In order to conclude that whether paricalcitol therapy had a comparative efficacy and safety over other VDRAs for treating dialysis patients with SHPT, the presently available evidence was insufficient. These findings called for a large-sample, well-conducted, high-quality RCTs with patient-level outcomes (i.e., mortality).
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries